International Pharmacovigilance Databases and Standards

International pharmacovigilance databases and standards are the shared repositories and terminologies that allow safety data from many countries to be pooled, compared, and analysed together. By coding reactions with a common dictionary and aggregating reports across borders, they multiply the statistical power available for detecting rare drug hazards.

Definition

International pharmacovigilance databases and standards comprise the cross-national repositories of individual case safety reports and the harmonised terminologies and data formats used to code and exchange them, enabling pooled analysis of medicine safety.

Scope

The entry covers why international pooling matters, the principal global infrastructure — the WHO Programme for International Drug Monitoring and its VigiBase database — and the standardised terminologies, above all MedDRA, that make reports interoperable. It is a reference overview of infrastructure and standards, not clinical guidance.

Core questions

• Why pool adverse-event reports across countries?
• What is the WHO Programme for International Drug Monitoring and VigiBase?
• What role do standard terminologies such as MedDRA play?
• How does harmonised coding support international signal detection?

Key concepts

• WHO Programme for International Drug Monitoring
• VigiBase (WHO global database)
• Uppsala Monitoring Centre
• MedDRA terminology
• Standardised case format (E2B)
• Data interoperability and harmonisation
• Pooled disproportionality analysis

Mechanisms

National pharmacovigilance centres forward individual case safety reports to a global repository — VigiBase, maintained by the Uppsala Monitoring Centre for the WHO programme — where reports from member countries accumulate together. To make those reports comparable, reactions and conditions are coded with a shared terminology, principally the Medical Dictionary for Regulatory Activities (MedDRA), and exchanged in standardised electronic formats. Pooling across countries enlarges the database so that disproportionality and Bayesian data-mining methods can detect rare drug-event associations that no single national database would contain enough reports to reveal (DuMouchel, 1999; Bate et al., 1998; WHO, 2002; Härmark & van Grootheest, 2008).

Clinical relevance

These databases and standards are the backbone of global drug-safety knowledge, and the terminologies they use also structure the safety information clinicians read. This entry describes the infrastructure and is not a basis for individual diagnostic or treatment decisions.

Epidemiology

International pooling is what gives pharmacovigilance the numbers to detect rare reactions: the WHO global database has grown to hold many millions of reports contributed by member countries, and harmonised coding allows the same drug-event analysis to be run across this combined resource (WHO, 2002; Härmark & van Grootheest, 2008).

History

The WHO international drug-monitoring programme began in 1968 with a small pilot of countries pooling adverse-reaction reports; its operations later centred on the Uppsala Monitoring Centre, which maintains the global database VigiBase. In parallel, the International Council for Harmonisation introduced MedDRA in the late 1990s to provide a single regulatory terminology, and standardised electronic case formats made cross-border exchange routine (WHO, 2002).

Debates

How comparable are reports pooled from heterogeneous systems?

Member countries differ in reporting culture, completeness, and coding practice, so pooled data carry uneven biases; how far cross-national comparisons and combined signal detection can be trusted is an ongoing methodological question.

Key figures

• I. Ralph Edwards
• Marie Lindquist
• Andrew Bate
• William DuMouchel

Seminal works

• dumouchel-1999
• who-umc-2002

Frequently asked questions

Why pool adverse-event reports internationally?

Rare reactions may generate too few reports in any single country to be detected. Pooling reports across many countries enlarges the database enough for statistical methods to identify rare drug-event associations.

What is MedDRA used for?

MedDRA is a standardised medical terminology for coding adverse events and other regulatory information, so that reports from different sources and countries describe the same reaction in the same way and can be analysed together.